final action
on 18 Dec 2024
Last Applicant/ Owned by
Route 206 & Province Line Road
Princeton
NJ
08543
Serial Number
98290537 filed on 29th Nov 2023
Registration Number
N/A
Correspondent Address
Xiomara Triana
Xiomara Triana Bristol-Myers Squibb Company
Trademark Dept., Mailstop D.4243
Princeton, NJ 08648-4000
United States
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloprol Read More
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; anticoagulants; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis.
N/A
N/A
No 98290537
No Service/Collective Mark
No 00163038-US
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
18th Dec 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
18th Dec 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
18th Dec 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
18th Sep 2024 | NON-FINAL ACTION WRITTEN |
18th Sep 2024 | NON-FINAL ACTION E-MAILED |
18th Sep 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
11th Sep 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
11th Sep 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
11th Sep 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
13th Jun 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |